[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anhedonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anhedonia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,51,92,119,149,177,203,228,251,279,317,350,374,408,436,468,493,518,540,569,592,613,641,666,688],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100595436","efficacy-of-ktmp-a-novel-non-invasive-brain-stimulation-method-for-the-treatment-of-anhedonia-100595436",false,"NCT07032428","Efficacy of kTMP, a Novel Non-invasive Brain Stimulation Method, for the Treatment of Anhedonia","kTMP Anhedonia","Inclusion Criteria: (1) Patients 21-80 years of age with clinically significant anhedonia, as defined by a SHAPS score of at least 20, and (2) Meet DSM-VTR diagnostic criteria for Major Depressive Disorder.\n\nExclusion Criteria:(1) Reason to anticipate possible hospitalization during the course of the study; (2) Current\u002Fhistory of a psychotic disorder, current manic or mixed episode, meeting the DSM-VTR criteria for bipolar disorder, post-traumatic stress disorder, schizophrenia, at screening, autism spectrum disorders, or mental retardation; (3) Meet DSM-VTR criteria for a substance use disorder within the last year; (4) Current suicidal ideation, suicidal ideation with intent, plan or attempt within the last year, or are considered at significant risk for suicide during the study; (5) Use of any drugs\u002Fmedications that may interfere\u002Finteract with the expected outcomes of the study within 5 half-lives of study participation (see Human Subject section for details); (6) History of seizure; (7) Intracranial expansive process; (8) Pacemaker or any metal implants in head\u002Fneck region; (9) Pregnancy; (10) Uncontrolled medical problems including but not limited to severe cardiovascular and cardiopulmonary disease, severe alcohol or drug abuse within the past year; (11) Contraindications for non-invasive brain stimulation or magnetic resonance imaging procedures; (12) Any other condition that in the opinion of the investigator would preclude participation in the study.","ALL","21 Years","80 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this proposal is to provide a first assessment of the efficacy of our innovative non-invasive brain stimulation system, kTMP, in the treatment of anhedonia in MDD.",[27,28],"Anhedonia","Major Depressive Disorder (MDD)",[30,31,32,33,34,35,36,37,38],"kTMP","NIBS","anhedonia","Major Depressive Disorder","Cortical Excitability","Plasticity","Neuroscience","reward network","kilohertz Transcranial Magnetic Perturbation","NOT_YET_RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-23","ACTUAL",{"date":45,"type":21},"2026-07-15",{"date":47,"type":21},"2028-07-30",{"name":49,"class":50},"Magnetic Tides","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":71,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100642005","reward-sensitivity-digital-intervention-for-suicide-risk-100642005","NCT07661901","Reward Sensitivity Digital Intervention for Suicide Risk","Pilot Development of a Youth-Focused Digital Just-in-Time Adaptive Intervention to Enhance Reward Sensitivity and Reduce Suicidal Ideation","DIGIReward","Inclusion Criteria:\n\nADOLESCENTS\n\n* Aged 13-17 years old\n* Recent suicidal ideation\n* Access to a smartphone device\n* Residing in the Philadelphia metropolitan area\n\nLEGALGUARDIANS\n\n* They are the legal guardian of an adolescent that meets all study criteria (see above)\n* They can read, write, and speak English\n\nExclusion Criteria:\n\nADOLESCENTS\n\n* Psychotic disorder, including schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified, with a past year psychotic episode prior to baseline\n* Bipolar disorder I diagnosis, with a past year manic episode prior to baseline\n* Imminent suicide risk (e.g., active suicidal ideation with a specific plan and intent)\n\nLEGALGUARDIANS\n\n\\- There are no exclusion criteria for legal guardians","13 Years","17 Years",{"count":62,"type":21},20,[24],"The goal of this clinical trial is to develop and test an app designed to reduce suicide risk and improve emotional well-being in adolescents. The study will test if the app's daily check ins and recommended mood boosting skills will improve the adolescent's overall mood and suicidality. The main question it aims to answer is:\n\n• Is the app practical and acceptable to use daily?\n\nIn the study, adolescents will:\n\n* Participate in a focus group with other adolescents and provide feedback on the app itself (design, ease of use, etc.).\n* Complete surveys and assessments on their mood, thoughts, and experiences.\n* Complete assessments about their app experience.\n\nIn the study, the legal guardian of the adolescent will:\n\n* Participate in a focus group with other adolescents and provide feedback on the app itself (design, ease of use, etc.).\n* Complete assessments about their app experience.",[66,67,68,69,70,27],"Suicidal Ideation","Suicidal","Suicidal Thoughts","Digital Health Intervention","Reward Sensitivity",[72,73,74,75,76,77,78,79,70,27],"Adolescents","Legal Guardians","Digital","Philadelphia","Suicide","Intervention","Prevention","Dyads","RECRUITING","2026-06-16",{"date":83,"type":43},"2026-06-22",{"date":85,"type":21},"2026-06",{"date":87,"type":21},"2027-09",{"name":89,"class":90},"University of Pennsylvania","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":91},"100643622","investigating-the-efficacy-and-mechanisms-of-individualized-tacs-targeting-anhedonia-in-late-life-depression-100643622","NCT07637773","Investigating the Efficacy and Mechanisms of Individualized tACS Targeting Anhedonia in Late-Life Depression","Efficacy and Mechanisms of Personalized tACS Targeting Anhedonia in Late-Life Depression","Inclusion Criteria:\n\n* (1) Patients were interviewed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Clinical Version (SCID-5-CV) to confirm that they met the DSM-5 diagnostic criteria for \"major depressive disorder\"; (2) Age ≥ 60 years; gender not restricted; (3) Hamilton Depression Scale (HAMD)-17 score \\> 24\n\nExclusion Criteria:\n\n\\- (1) History of severe head trauma or serious neurological conditions such as epilepsy; (2) Any brain devices or implants, including cochlear implants and aneurysm clips; treatments such as transcranial direct current stimulation (tDCS).\n\n(3) Individuals who have undergone other physical modulation therapies within the past 8 weeks, including but not limited to non-convulsive electroconvulsive therapy, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation.","60 Years",{"count":101,"type":21},80,[24],"This project focuses on clinical translational research into personalized transcranial alternating current stimulation (tACS) for treating anhedonia in late-life depression (LLD). Key components include: (1) Optimizing individualized tACS treatment parameters through randomized, double-blind, controlled trials and establishing precise treatment protocols using deep learning algorithms; (2) Assessing the short-term (2 weeks) and long-term (3 months) efficacy of tACS on depressive symptoms and anhedonia using scales such as the HAMD, SHAPS, and DARS, while monitoring safety; (3) Integrating multimodal detection technologies (64-channel EEG, inflammatory factors\u002Fneurotransmitters, etc.) to elucidate the mechanisms by which tACS alleviates anhedonia through modulating prefrontal neural oscillations (y-band), improving synaptic plasticity (increased BDNF), and regulating neurotransmitters (5-HT, DA). This study will establish, for the first time, an individualized parameter system for tACS treatment of LLD, providing a novel non-pharmacological intervention strategy for clinical practice.",[105,27],"Late-Life Depression",[107,108,32,109],"transcranial alternating current stimulation","late-life depression","Brain function","2026-06-09",{"date":112,"type":43},"2026-06-10",{"date":114,"type":43},"2026-03-16",{"date":116,"type":21},"2027-12-31",{"name":118,"class":90},"Jie Li",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100579873","get-active-study-for-at-risk-youth-100579873","NCT06829953","Get ActivE Study for At-risk Youth","Geospatial and Ecological Momentary Assessment Technology and Activity Engagement for At-risk Youth (Get ActivE)","GetActivE","Inclusion Criteria:\n\n* Adolescents age 12-18\n* Current moderate to severe depression (PHQ-9-M \\> 11)\n* Current clinically significant anhedonia, operationalized as PHQ-9-M anhedonia item score \\> 1\n* English language fluency and literacy level sufficient to engage in study protocol\n* Willing to download the app on their smart phones\n\nExclusion Criteria:\n\n* Evidence of mania, psychosis, or developmental disability precluding comprehension of study procedures per electronic health record review and phone screen.","12 Years","18 Years",{"count":130,"type":21},75,[24],"The study will adapt and deploy a digital Behavioral Activation app with mobile sensing, supported by health coaches, that encourages youth to engage in positive activities. The study has the potential to offer a low-cost and scalable behavioral intervention that may decrease risk of suicide among at-risk youth. This research will examine specifically whether an intervention involving an app called Vira, combined with health coaching (GET ActivE) can improve enjoyment for teens coping with depression. Research participants will be randomly assigned to one of two study intervention. One study intervention involves a) downloading an app called Vira and engaging by responding to a daily question, and b) participating in a conversation via text, phone, or messages through an appt with a health coach. The health coach will use the Vira app and principles from evidence-based therapy and behavior change to provide users with insights to sustain well-being and better manage risk factors for suicidal thoughts and behaviors such as depressed mood and behavioral withdrawal. The second study intervention involves downloading an app called EARS and responding to a daily question.",[27,134],"Depression and Suicide Ideation",[136,137,27,138,76],"Behavioral Activation","Health Coach","Minority Youth","2026-06-02",{"date":141,"type":43},"2026-06-04",{"date":143,"type":43},"2025-03-27",{"date":145,"type":21},"2026-12-31",{"name":147,"class":90},"University of Pittsburgh",2,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":16,"minAge":128,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":91},"100565921","multimodal-differences-in-effort-based-decision-making-in-depression-100565921","NCT06648460","Multimodal Differences in Effort-based Decision-Making in Depression","Multimodal Differences in Effort-based Decision-Making in Depression - - Brain Behavior Quantification and Synchronization","BBQS","Inclusion Criteria:\n\n* Matched control group\n\n  * 18-65 years old\n  * Able-bodied\n  * Fluent in English\n  * Able to give written and verbal informed consent to the proposed experiment\n  * Able to comprehend the study procedure, potential risks, and benefits\n* Group with depression\n\n  * Diagnosed with major depression\n  * Quick Inventory of Depression Symptomology (QIDS) score \\> 5\n  * 18-65 years old\n  * Able-bodied\n  * Fluent in English\n  * Able to give written and verbal informed consent to the proposed experiment\n  * Able to comprehend the study procedure, potential risks, and benefits\n\nExclusion Criteria:\n\n* Matched control group\n\n  * Current diagnosed psychiatric disorder (e.g., anxiety, depression, bipolar disorder)\n  * Current pregnancy\n  * BMI \\> 35\n  * Currently on antipsychotics\n* Group with depression\n\n  * Diagnosed with psychotic symptoms\n  * Diagnosed with other neurological or psychiatric disorders\n  * Current pregnancy\n  * BMI \\> 35\n  * Currently on antipsychotics",true,"65 Years",{"count":160,"type":21},90,[24],"Major depressive disorder (MDD) is a serious condition that causes long-term symptoms such as feeling sad, losing interest in activities, and having thoughts of self-harm. Difficulty in making an effort is a key factor in functional impairment. Current methods to evaluate this difficulty use clinical assessments and computer-based tasks, but there is a gap between the measurements and real-life behavior. To address this, the study team proposes creating an instrumented behavioral test, HORMES, to objectively assess reduced motivation during everyday activities and measure physiological responses. The study will examine differences in brain activity, autonomic system function, and metabolic energy expenditure in patients with major depression during a decision-making task that involves physical effort.",[164,27],"Depression",[166,167],"Effort-based decision-making","Physical Effort","2026-06-01",{"date":170,"type":43},"2026-06-03",{"date":172,"type":21},"2026-08-01",{"date":174,"type":21},"2030-09-30",{"name":176,"class":90},"Georgia Institute of Technology",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":158,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":148},"100504492","phase-2-inflammation-and-depression-in-people-with-hiv-100504492","NCT05849038","Inflammation and Depression in People With HIV","The Role of Inflammation in Central Nervous System (CNS) Mechanisms of Anhedonia and Psychomotor Slowing in Depressed People With HIV","Inclusion Criteria:\n\n* HIV infected on continuous antiretroviral therapy (ART) with plasma HIV RNA \\\u003C200 copies\u002Fml for at least 12 months (on at least two previous clinic visits and confirmed at screening)\n* Current cluster of differentiation 4 (CD4+) \\> 350 cells\u002Fmicroliter for at least twelve months (on at least two previous clinic visits and confirmed at screening)\n* A primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) major depression, current, or Bipolar, depressed type as diagnosed by the SCID-V\n* Score of ≥10 on the 9-item Patient Health Questionnaire (PHQ-9)\n* Off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks prior to baseline visit\n* Significant anhedonia as reflected by a score ≥ 2 on item #1 of the PHQ-9\n* CRP≥2mg\u002FL\n* Women of reproductive age will have a negative serum pregnancy test at study entry and both men and women must agree to adequate contraception while\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age or \\> 65 years of age\n* Pregnancy or breastfeeding\n* Significant hematological abnormalities at screening (ANC \\\u003C 1500, Hgb\\\u003C10, platelet\\\u003C 100,000)\n* History of progressive multifocal leukoencephalopathy\n* Untreated latent tuberculosis infection (which will be screened for prior to entry)\n* Having taken the following immunosuppressive medications within the past 6 months:\n\n  1. Oral corticosteroids\n  2. Biologic treatments such as etanercept, infliximab, certolizumab, adalimumab, golimumab, tocilizumab, abatacept, Ustekinumab, ixekizumab, secukinumab, or anakinra\n  3. Cyclophosphamide (or any other cytotoxic agent), belimumab, or anifrolumab (or another anti-interferon (IFN) therapy)\n  4. Rituximab, any other B cell depleting therapies, or intravenous immunoglobulin (IVIg)\n  5. any Janus kinase (JAK) inhibitor\n* History of deep venous thrombosis\n* Cardiovascular disease:\n\n  1. Coronary artery disease or history of myocardial infarction\n  2. Congestive heart failure with left ventricular ejection fraction ≤40% per American Heart Association guidelines\n  3. Stroke history\n* Hematologic malignancies including lymphoma and leukemia\n* Major surgery within 8 weeks prior to screening or will require major surgery during the study\n* Current or recent (\\\u003C4 weeks prior to randomization) clinically serious viral (including coronavirus disease 2019 (COVID-19)), bacterial, fungal, or parasitic infection or any other active or recent infection\n* Symptomatic herpes simplex at the time of randomization\n* Symptomatic herpes zoster infection within 12 weeks prior to randomization\n* History of disseminated\u002Fcomplicated herpes zoster (for example, ophthalmic zoster or CNS involvement)\n* Positive test for hepatitis B virus (HBV) defined as:\n\n  1. positive for hepatitis B surface antigen (HBsAg), or\n  2. positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA)\n* Hepatitis C virus (HCV) infection (hepatitis C antibody-positive and HCV ribonucleic acid \\[RNA\\]-positive)\n* Cirrhosis of the liver from any cause\n* Any of the following specific abnormalities on screening laboratory tests:\n\n  1. alanine transaminase (ALT) or aspartate aminotransferase (AST) \\>2 x upper limits of normal (ULN)\n  2. alkaline phosphatase (ALP) ≥2 x ULN\n  3. total bilirubin ≥1.5 x ULN (with the exception of patients on atazanavir, who must have total bilirubin \\\u003C2 x ULN)\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C40 mL\u002Fmin\u002F1.73 m\\^2\n* History of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; substance abuse\u002Fdependence within 6 months of study entry, as determined by severe combined immunodeficiency (SCID)\n* A positive urine drug screen for illicit drugs at any time during the study excluding marijuana\n* An active suicidal plan as determined by a score \\>3 on item #3 on the Hamilton Rating Scale for Depression (HAM-D)\n* An active eating disorder or antisocial personality disorder\n* History of dementia\n* Chronic use of glucocorticoid containing medications or minocycline within 2 weeks of baseline or at any time during the study\n* Any contraindication for MRI scanning\n* Failure of more than 2 antidepressant trials (at least 6 weeks at recommended dose) in the current episode or 5 antidepressant trials lifetime\n* BMI \\>42 (to exclude severe obesity) or at the investigator's discretion based on the patient's ability to fit in the MRI scanner",{"count":185,"type":21},60,[187],"PHASE2","The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male and female patients with HIV who have depression, anhedonia and high inflammation and are stable on effective treatment for their HIV will be randomized to receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks. Participants will complete lab tests, medical and psychiatric assessments, neurocognitive testing, functional MRI (fMRI) scans, and optional spinal taps as part of the study.",[190,164,27],"HIV",[192,27,193],"Human Immunodeficiency Virus (HIV)","Psychomotor Slowing","2026-05-23",{"date":196,"type":43},"2026-05-28",{"date":198,"type":43},"2023-12-11",{"date":200,"type":21},"2027-11",{"name":202,"class":90},"Emory University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":158,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":91},"100638545","phase-1-psilocybin-as-a-novel-therapy-for-residual-anhedonia-100638545","NCT07607938","Psilocybin as a Novel Therapy for Residual Anhedonia","Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Able to provide voluntary signed and dated informed consent.\n* Females of childbearing potential (FOCBP) must agree to practice an effective means of birth control throughout the duration of the trial\n* Males who have FOCBPs as partners must agree to practice an effective means of birth control throughout the duration of the trial\n* State willingness to comply and be available for all study requirements, including psychological, cognitive, imaging and procedural evaluations for the duration of the study\n* Meet DSM-5 criteria for major depressive disorder (MDD)\n* Screening Dimensional Anhedonia Rating Scale (DARS) total score of \\\u003C 28.5 points\n* Have an identified support person\n* Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator.\n\nExclusion Criteria:\n\n* Inability to speak and understand English sufficiently to complete informed consent and study procedures.\n* Inability to provide informed consent.\n* Women who are pregnant or who intend to become pregnant or nurse during the study duration.\n* Prior exposure to classic psychedelics (i.e., psilocybin, LSD, ayahuasca, and\u002For mescaline) within the past 1 year.\n* Current or previous psychiatric conditions that meet DSM-5 criteria for psychotic disorders (i.e., schizophrenia, schizoaffective disorder, MDD with psychosis), bipolar 1 or 2 disorder, or current diagnosis of active substance use disorder.\n* Have active suicidal ideation with intent, based on Columbia-Suicide Severity Rating Scale (C-SSRS assessment (severity score \\> 3) at the Screening visit, confirmed by the Investigator.\n* Have made a medically significant suicide attempt (i.e., one that had a significant possibility of causing death or permanent harm in the absence of intervention) within the past 12 months, based on Screening C-SSRS assessment and confirmation by the Investigator.\n* Immediate family history (i.e., parents, full siblings, or half siblings) with known or suspected psychotic disorder.\n* Presence of medical conditions that may confound results of imaging study or that are contraindications to or psilocybin exposure (i.e., neurological, renal, hypertension, metabolic or cardiovascular disease or pregnancy);\n* Presence of contraindications to MRI scanning (implantable devices, bone hardware, various IUD).\n* Participants who received electroconvulsive therapy (ECT), trans magnetic cranial stimulation (TMS), and\u002For ketamine in the past 90 days.\n* Has any other physical or psychological symptom, medication, or other relevant finding prior to randomization that, based on the clinical judgment of trial personnel, would make a participant unsuitable for the trial.\n* Are unable or unwilling to discontinue taking any protocol-prohibited medications and supplements.",{"count":160,"type":21},[212],"PHASE1","The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).",[27,215],"Emotional Blunting",[217,218,164,27,215,219],"SSRI","SNR","Psilocybin","2026-05-19",{"date":222,"type":43},"2026-05-27",{"date":224,"type":21},"2026-07",{"date":174,"type":21},{"name":227,"class":90},"NYU Langone Health",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":157,"sex":16,"minAge":128,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":91},"100515454","geolocation-positional-system-gps-experience-100515454","NCT05991713","Geolocation Positional System (GPS) Experience","Individual Differences in Emotional and Behavioral Patterns and Their Relationship to Cognition","Inclusion Criteria:\n\n* Must agree to give informed consent\n* Must be willing to have an functional Magnetic Resonance Imaging (FMRI) scan\n* Must be able to receive and respond to daily text messages assessing current emotion\n* Must be willing to download and run a GPS tracking application (FollowMee) onto their smartphone for a four-month period\n\nExclusion Criteria:\n\n* history of head trauma, seizures, or neurological disorders\n* severe\u002Funstable medical conditions\n* conditions that interfere with MRI\n* pregnancy\n* lifetime psychotic\u002Fbipolar disorder\n* chronic\u002Fsevere substance or alcohol abuse\u002Fdependence\n* antipsychotic medication","50 Years",{"count":237,"type":21},100,[24],"The purpose of this study is to use smartphone technology to capture individual location emotional and cognitive data, to examine how real-world behaviors thoughts, emotions, and brain activity are related to one another.",[241,27,164],"Emotions","2026-04-29",{"date":244,"type":43},"2026-05-05",{"date":246,"type":43},"2023-11-02",{"date":248,"type":21},"2028-09-01",{"name":250,"class":90},"University of Miami",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":157,"sex":16,"minAge":128,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":266,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":91},"100617478","the-effect-of-transcranial-direct-current-stimulation-tdcs-in-improving-emotion-health-100617478","NCT07319143","The Effect of Transcranial Direct Current Stimulation (tDCS) in Improving Emotion Health","Utilizing Transcranial Direct Current Stimulation (tDCS) to Alleviate Subthreshold Depression Via Distinct Positive and Negative Emotion Pathways","Inclusion Criteria:\n\n* Age 18-35 years\n* Fluency in Cantonese or Mandarin\n* Normal or corrected-to-normal vision and hearing\n* IQ \\> 75% Quantile in Raven's SPM\n* At least 9 years of formal education\n* Right-handedness\n\nExclusion Criteria:\n\n* Past or current major physical illness or psychiatric disorders\n* Use of psychotropic medication in the past 6 months\n* Pregnancy (for women)\n* Any condition that prevents safe tDCS use (e.g., brain injury, implants)\n* Previous participation in neuromodulation in the past 3 months","35 Years",{"count":160,"type":21},[24],"The goal of this clinical trial is to investigate how transcranial direct current stimulation (tDCS) affects emotion functions in young adults aged 18-35 from the local community, including both male and female participants. The main question\\[s\\] it aims to answer are:\n\n* Does tDCS improve emotional functions, such as mood regulation and motivation, in individuals with subthreshold depression (StD)?\n* Can tDCS enhance emotional regulation compared to a sham stimulation (placebo)?\n\nResearchers will compare participants receiving tDCS on either the left dorsolateral prefrontal cortex (lDLPFC) or right ventrolateral prefrontal cortex (rVLPFC) with those receiving sham stimulation to see if tDCS has a stronger effect on emotional functions.\n\nParticipants will:\n\n* Complete online and in-person screening to assess depressive symptoms using the Chinese version of the Beck Depression Inventory II (C-BDI-II) and be selected based on their depressive symptoms (C-BDI-II score ≥ 13).\n* Be randomly assigned to one of three groups: lDLPFC tDCS, rVLPFC tDCS, or Sham control group (1:1:1 ratio).\n* Receive 10 sessions of tDCS or Sham tDCS over 2 weeks, with each session lasting 20 minutes.\n* Complete assessments at baseline, post-intervention, 1-month follow-up, and 3-month follow-up, with each assessment lasting 2-2.5 hours. This includes questionnaires and perform emotional and cognitive tasks.",[263,264,265,27],"Subthreshold Depression","Positive Emotions","Negative Emotions",[267,263,268,269],"Transcranial Direct Current Stimulation","Emotion","Neuromodulation","2026-04-28",{"date":272,"type":43},"2026-05-04",{"date":274,"type":43},"2026-01-08",{"date":276,"type":21},"2027-09-01",{"name":278,"class":90},"The University of Hong Kong",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":287,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":91},"100460949","phase-4-examining-the-effects-of-estradiol-on-neural-and-molecular-response-to-reward-100460949","NCT05282277","Examining the Effects of Estradiol on Neural and Molecular Response to Reward","Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis","PEEPS","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures, lifestyle considerations, and availability for the duration of the study\n* 44-55 years old unmedicated perimenopausal women who have ≥ 2 skipped menstrual cycles, amenorrhea ≥ 60 days, corresponding to the late menopause transition (Stages of Reproductive Aging Workshop (STRAW stage -1).\n* Anhedonia or psychosis symptoms that began during the period of menstrual irregularity.\n* Clinician's Global Impression Scale-Severity score (CGI-S) \\> 3 to confirm a clinically impaired sample.\n* Anhedonia severity inclusion criteria and stratification: All participants will have Snaith-Hamilton Pleasure Scale (SHAPS) scores \\> 20 consistent with the NIMH Fast-Fail Trial for Mood and Anxiety Disorders, corresponding to clinically impairing anhedonia.\n* Psychosis severity inclusion criteria and stratification: Participants will be stratified according to scores on the psychotic subscale of the Brief Psychiatric Rating Scale (BPRS)\n* Willingness to adhere to the estradiol regimen\n\nExclusion Criteria:\n\n* Pregnancy; allergies to any active or inactive ingredients in the Climara® patch or Prometrium®.\n* BMI \\\u003C 18 or \\> 35 kg\u002Fm\\^2\n* A history of chronic menstrual cycle irregularity, meaning \\> 1 year without menses\n* MR contraindications: Metal in the body, dental work other than fillings or gold, tattoos, metal injury, any other implant unless they are 100% plastic.\n* PET contradictions: participation in \\>1 research study in the past 12 months that included ionizing radiation exceeding 3 rem to the whole body (e.g., PET, CT). Standard of care imaging is not exclusionary.\n* The use of psychotropics or hormonal preparations.\n* History of psychiatric illness during the 2 years before the onset of perimenopause.\n* History of chronic, recurrent mood or psychotic disorders (i.e., more than one non-reproductive-related mood episode prior to the perimenopausal index episode).\n* A history of mood episodes requiring hospitalization.\n* Current mania;\n* Depressive episode(s) within 2 years of enrollment not associated with the transition to menopause;\n* A history of suicide attempts within the last year or current active suicidal ideation with intent and plan.\n* Neurological conditions (e.g., history of seizure or TBI)\n* Brain stimulation treatment in the past six months.\n* Endometriosis;\n* First degree relative with premenopausal breast cancer or breast cancer presenting in both breasts or multiple family members (greater than three relatives) with postmenopausal breast cancer.\n* Current medication use (i.e., current psychotropics, current anti-hypertensives, current statins, current hormonal preparations, or frequent use of anti-inflammatory agents (\\> 10 times\u002Fmonth)). Women will be allowed to enroll who take medications without known mood effects (e.g. stable thyroid hormone replacement and occasional (\\\u003C 5 times\u002Fmonth) use of Ambien)\\*;\n* Pregnant, breastfeeding or trying to conceive;\n* Last menstrual period more than 12 months prior to enrollment;\n* History of undiagnosed vaginal bleeding;\n* Undiagnosed enlargement of the ovaries;\n* Polycystic ovary syndrome;\n* History of breast or ovarian cancer;\n* First degree relative with ovarian cancer;\n* Abnormal finding in a provider breast exam and\u002For mammogram;\n* Known carrier of BRCA1 or 2 mutation;\n* Porphyria;\n* Malignant melanoma;\n* Hodgkin's disease;\n* Recurrent migraine headaches that are preceded by aura;\n* Gallbladder or pancreatic disease\\*\\*;\n* Heart or kidney disease\\*\\*;\n* Liver disease;\n* cerebrovascular disease (stroke);\n* First degree relative with history of heart attack or stroke;\n* Current nicotine use;\n* Self-reported claustrophobia\n* Peanut allergy\n\n  * all reported prescription medications will be reviewed and cleared by a study physician prior to a participant's enrollment;\n\n    * participants will be given the opportunity to describe these conditions in the online screening survey. Reported conditions that are acute in nature and\u002For benign will be reviewed by a study physician and exclusions will be decided case-by-case. All chronic conditions will be exclusionary. For those where it is deemed that an exclusion does not apply, primary analyses will not be affected, but exploratory analyses will be conducted excluding these individuals","FEMALE","45 Years","55 Years",{"count":291,"type":21},103,[293],"PHASE4","This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).",[164,296,27],"Psychosis",[298,27,299,300,301,302,303,304,305,306,307,308,309,310],"Reproductive Affective Disorder","Perimenopause","Estrogen","Hormone Replacement Therapy","Mood Disorders","Estradiol Treatment","Sex Steroids","Psychosis Symptoms","Depressive Disorders","Estradiol","Hormones","Reward Activation","Reproductive Control Agents",{"date":242,"type":43},{"date":313,"type":43},"2022-04-20",{"date":145,"type":21},{"name":316,"class":90},"University of North Carolina, Chapel Hill",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":158,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":327,"briefSummary":328,"conditions":329,"keywords":335,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":91},"100523519","psychotherapy-effects-on-reward-processing-in-ptsd-100523519","NCT06096740","Psychotherapy Effects on Reward Processing in PTSD","The Effects of Trauma-focused Psychotherapy on Reward Circuitry Function and Information Encoding","PERPP","Inclusion Criteria:\n\n* English as primary language, and comprehension suitable to understand experimenter instructions.\n* Current and chronic syndromic PTSD, defined as being exposed to a DSM-5 Criterion A traumatic event, with the presence DSM-5 qualifying PTSD symptoms for at least 3 months, as assessed by the Clinician-Administered PTSD Scale for DSM-5.\n* Able and willing to undergo functional magnetic resonance imaging (fMRI).\n* Willingness to participate in repeated assessments and as part of a delayed treatment group.\n\nExclusion Criteria:\n\n* Evidence of current or prior history of psychosis or bipolar disorder as evidenced by self-report or clinical interview.\n* Active substance dependence within the past 6 months as evidenced by clinical interview.\n* Current regular psychiatric medication use (i.e. antidepressants), except for as-needed benzodiazepine or opiate medication no more than three times per week, on average, or for short-duration stimulant medication for attention deficit hyperactivity disorder that can be skipped within 24 hours of study visits.\n* A recent (\\\u003C6 months) suicide attempt or current active ideation with intent.\n* Unremovable ferrous metal in body.\n* History of neurological disorder, stroke, seizures\u002Fconvulsions (except febrile seizures in childhood), epilepsy, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, or thyroid disorder.\n* Anyone who is pregnant or trying to become pregnant.\n* Current or past year (\\> 3 sessions), psychotherapy with a prominent exposure or cognitive restructuring component.\n* Previous or current (es)ketamine treatment and\u002F or brain stimulation\u002Fneuromodulation treatment.\n* Other ongoing treatment that is likely to confound experimental effects.\n* Previous penetrating head injury\u002Ftraumatic brain injury. Mild-to-moderate traumatic brain injury without penetrating injury is allowable.",{"count":326,"type":21},120,[24],"The purpose of this study is to identify how trauma-focused psychotherapy changes the function of brain circuitry in posttraumatic stress disorder (PTSD) and how this mediates improvements in the diminished ability to experience positive emotions following a traumatic or extremely stressful life event. In this instance, the investigators will be using cognitive processing therapy (CPT), a widely-utilized and evidence-based treatment for PTSD.",[330,331,27,332,333,334],"Post Traumatic Stress Disorder","Diminished Pleasure","PTSD","Chronic PTSD","Chronic Post-Traumatic Stress Disorder",[332,336,337,338,339,340,333],"Post Traumatic Stress","Emotional Numbing","CPT","Cognitive Processing Therapy","Therapy","2026-04-27",{"date":343,"type":43},"2026-05-01",{"date":345,"type":43},"2024-06-01",{"date":347,"type":21},"2029-05-01",{"name":349,"class":90},"University of Texas at Austin",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":359,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":148},"100598956","long-term-follow-up-of-depressive-disorders-in-psychiatric-care-100598956","NCT07078227","Long-term Follow-up of Depressive Disorders in Psychiatric Care","5 Years Follow-up of the Study: \"Pharmacogenetics in Depressed Patients With Specific Focus on Difficult-to-treat Depresssion, Suicide Attempt and CYP2D6\"","Inclusion Criteria:\n\nParticipation in the study \"Pharmacogenetics in depressive patients with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6\"\n\nExclusion Criteria:\n\nNot wanting to participate in the follow-up study",{"count":358,"type":21},415,"OBSERVATIONAL","The project investigates long-term prognosis and predictors of treatment outcomes for difficult-to-treat depression in patients in secondary psychiatric care. The current patient cohort was collected in 2012-2021 in the study \"Pharmacogenetics in patients with depression with specific focus on difficult-to-treat depression, suicide attempt and CYP2D6\". The cohort consists of 415 patients, examined carefully regarding diagnostic assessment and earlier treatment. All participants were also genotyped for the drug metabolizing enzymes CYP2D6 and CYP2C19. Blood samples were stored in biobank for other analyses linked to prognostic markers.\n\nThe patient cohort will now be followed up with a review of medical records and extraction of register data for a period of 5 years after their participation in the original study. The purpose of the study is to improve treatment and increase knowledge about long-term prognosis in difficult-to-treat depression. This is done by examining symptom profiles, monitoring clinical course and suicidality, and examining prognostic markers.",[164,362,363,364,365,27],"Psychiatric Diagnosis","Personality Disorders","Suicide, Attempted","CYP2D6 Polymorphism","2026-04-24",{"date":368,"type":43},"2026-04-30",{"date":370,"type":43},"2025-06-01",{"date":145,"type":21},{"name":373,"class":90},"Region Skane",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":99,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":391,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":148},"100575800","reward-processing-and-exposure-therapy-for-social-anxiety-disorder-100575800","NCT06776991","Reward Processing and Exposure Therapy for Social Anxiety Disorder","Reward Processing and Exposure Therapy","METER","Inclusion Criteria:\n\n* Diagnosis of social anxiety disorder from the Structural Clinical Interview for DSM 5.\n* Elevated fear of public speaking, defined as a score of \\>= 66 (+1SD from the mean of population norms on a scale of 17-85) on the Public Speaking Anxiety Scale (PSAS; Bartholomay, E. M., \\& Houlihan, D. D. (2016). Public Speaking Anxiety Scale: Preliminary psychometric data and scale validation. Personality and individual differences, 94, 211-215), which is a self-report scale measuring anxiety of public speaking.\n* Low reward processing, defined as a score of \\\u003C56 (less than the population mean) on the Dimensional Anhedonia Rating Scale (DARS) (Rizvi, S. J., Quilty, L. C., Sproule, B. A., Cyriac, A., Bagby, R. M., \\& Kennedy, S. H. (2015). Dimensional Anhedonia Rating Scale (DARS) \\[Database record\\]. APA PsycTests).\n* Medication-free or stabilized on psychotropic medications for a minimum standard length of time (1 month for benzodiazepines and beta blockers, 3 months for SRIs\u002FSNRIs and heterocyclics).\n* Psychotherapy-free or stabilized on alternative psychotherapies other than cognitive or behavioral therapies that were not focused on their anxiety disorder for at least 6 months prior to study entry.\n* Age 18-60.\n* Fluent in English.\n* To conduct MRI version of fear conditioning task, must have no MRI contraindications.\n\nExclusion Criteria (none of the following):\n\n* Recent suicidal ideation with intent or plan - defined as suicidal ideation with intent or plan in the past year.\n* Lifetime history of suicide attempts.\n* History of bipolar disorder, psychosis, intellectual disability, or organic brain damage.\n* Substance use disorder within the last 6 months.\n* Major respiratory, cardiovascular, pulmonary, neurological, or muscular-skeletal diseases.\n* Pregnant or planning to become pregnant for next 6 months.",{"count":383,"type":21},94,[24],"The investigators are conducting a clinical trial of therapy for public speaking anxiety. There are many eligibility criteria, but the main ones are that participants need to be socially anxious and have public speaking anxiety. In this clinical trial, all participants will do exposure therapy. Before doing exposure therapy in the study, though, participants will be randomized to do one of two treatments: i) a positive mood treatment, which is designed to increase how positive people feel, and ii) a relaxation treatment, which is designed to help people feel more relaxed. The investigators are doing this study to see whether doing the positive mood treatment or relaxation treatment first will affect how well exposure therapy works.",[387,388,27,389,390],"Social Anxiety Disorder (Social Phobia)","Public Speaking Anxiety","ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)","Phobic Disorders",[392,393,394,388,27,395,396,397,398],"Exposure Therapy","Anxiety","Social Anxiety","Reward Processing","Inhibitory Retrieval","Positive Affect Treatment","Relaxation Treatment","2026-04-01",{"date":401,"type":43},"2026-04-02",{"date":403,"type":43},"2024-09-26",{"date":405,"type":21},"2029-04-30",{"name":407,"class":90},"University of California, Los Angeles",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":359,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":435},"100604206","esketamine-nasal-spray-in-real-world-settings-in-treatment-resistant-depression-100604206","NCT07146503","Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways","ESKPSY","Inclusion criteria were: (a) age 18-74, (b) DSM-5 diagnosis of a major depressive episode (MDE), (c) failure to respond to at least 2 prior antidepressant treatments (ADTs), and (d) current treatment with an SSRI or SNRI for which esketamine nasal spray was deemed appropriate.","74 Years",{"count":237,"type":21},"This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.",[420,421,27,422,393,423,424,425],"Depression and Quality of Life","Treatment Resistant Depression (TRD)","Apathy","Cognition","Temperament","Psychiatric Comorbidities","2026-03-25",{"date":428,"type":43},"2026-03-31",{"date":430,"type":43},"2022-11-01",{"date":432,"type":21},"2030-08",{"name":434,"class":90},"Riccardo Guglielmo",5,{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":157,"sex":16,"minAge":128,"maxAge":289,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":91},"100630644","phase-1-elucidating-the-relevance-of-the-psychedelic-experience-to-psilocybins-anti-anhedonic-effects-100630644","NCT07490353","Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial","Inclusion criteria:\n\nAll participants:\n\n* General health based on medical history, physical examination, blood draw, and electrocardiogram\n* Age 18 to 55 years\n* Right-handedness (due to potential lateralization effects of left-handed subjects)\n* Willingness and competence to sign the informed consent form\n* Normal BMI weight range (18.5-24.9)\n\nSpecific to healthy subjects:\n\n* Psychiatric health based on structured clinical interview for DSM-5 (SCID)\n* No concomitant medication\n\nSpecific to anhedonia patients:\n\n* Major depressive episode (first or recurrent) based on structured clinical interview for DSM-5 (SCID) and ICD-10\n* Fulfilling the ICD-10 diagnostic criterion of anhedonia\n* No concomitant medication, specifically also free of antidepressants or other psychopharmaceuticals (for at least 2 weeks, 5 weeks for fluoxetin)\n\nExclusion criteria:\n\nAll participants:\n\n* Current or history of neurological disease\n* Current medical illness requiring treatment\n* Pregnancy or current breastfeeding\n* Current or former substance dependency\n* Any contraindication for MRI\n* Failure to comply with the study protocol or to follow the instruction of the investigating team\n* Failure to confirm effective use of contraception in females at least 8 weeks before and after study participation each\n* First-degree relative with bipolar disorder or schizophrenia\n\nSpecific to healthy subjects:\n\n\\- Psychiatric diagnosis\n\nSpecific to anhedonia patients:\n\n\\- Psychiatric comorbidities excluding anxiety disorders and\u002For obsessive-compulsive disorders",{"count":444,"type":21},85,[212],"The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are:\n\nPrimary Objectives\n\n1. Systematically categorize prohedonic effects (antianhedonic effects in patients with anhedonia in depression, increase in well-being in all participants).\n2. Test effects of psilocybin on brain network complexity measures during the hedonic experience using fMRI as a correlate for prohedonic (anti-anhedonic and well-being increasing) effects.\n3. Elucidate relevance of the psychedelic experience to these effects (clinical, behavioral, and imaging) in a pharmacological challenge using the 5-HT2A\u002FD2 antagonist risperidone and extensive characterization of the psychedelic experience. Secondary Objectives 4. Test the differential effects of the psychedelic experience on fMRI paradigms measuring symptoms shown to be altered in anhedonia, more specifically reward processing and sexual arousal. 5. Test the relevance of neuroplasticity (BDNF) and inflammatory parameters to anti-anhedonic, well-being promoting, and brain network dynamic complexity effects. 6. Test the effects of the psychedelic experience on BDNF and inflammatory parameters.\n\nResearchers will compare the effects of psilocybin in two separate sessions (one with psilocybin alone, one with co-administration of risperidone) in both patients with depression and anhedonia and healthy control participants.\n\nParticipants will:\n\n* Take 25 mg of psilocybin p.o. in two sessions, in one of the two sessions they will take 1 mg risperidone p.o. before ingestion of psilocybin, to block psilocybin's acute psychedelic effects.\n* Undergo 3 MRI sessions, one before the first psilocybin session ('baseline') and one session each on the day after each respective psilocybin session.\n* Perform a variety of tasks during each fMRI session to asses the treatment's effects on anhedonia.",[448,27],"Depression - Major Depressive Disorder",[219,450,451,27,164,452,453,454,455,456,457,458],"Psilocin","Psychedelic","MRI","fMRI","functional MRI","Pharmaco-Imaging","MDD","Serotonin","Risperidone","2026-03-19",{"date":461,"type":43},"2026-03-24",{"date":463,"type":43},"2025-11-01",{"date":465,"type":21},"2028-05-31",{"name":467,"class":90},"Medical University of Vienna",{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":158,"enrollmentInfo":475,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":91},"100526272","causal-role-of-delta-beta-coupling-for-goal-directed-behavior-in-anhedonic-depression-100526272","NCT06132581","Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression","DBA","Inclusion Criteria:\n\n* Between the ages of 18 and 65\n* Able to provide informed consent\n* Have normal to corrected vision\n* Willing to comply with all study procedures and be available for the duration of the study\n* Speak and understand English\n* Mild suicide risk as determined by the Hamilton Depression Rating Scale (HAM-D; less than 3 for the suicidality item) and non-existent or mild risk according to the Depression Symptom Index Suicidality Subscale (DSI-SS).\n* Patient Health Questionnaire (PHQ-8) greater than or equal to 8 prior to the first session\n* Snaith Hamilton Pleasure Scale (SHAPS) greater than 33 at the first session\n* A diagnosis of major depressive disorder on the Mini International Neuropsychiatric Interview for the DSM-V (MINI)\n\nExclusion Criteria:\n\n* ADHD (currently under treatment)\n* Neurological disorders and conditions including, but not limited to history of epilepsy; seizures, except childhood febrile seizures; dementia; history of stroke; Parkinson's disease, multiple sclerosis, cerebral aneurysm; brain tumors\n* Medical or neurological illness or treatment for a medical disorder that could interfere with study participation. For example, unstable cardiac disease, HIV\u002FAIDS, malignancy, liver or renal impairment\n* Prior brain surgery\n* Any brain devices\u002Fimplants including cochlear implants and aneurysm clips, cardiac pacemaker, or any other implanted electronic device\n* History of current traumatic brain injury\n* Pregnancy (for females)\n* Current severe substance use disorder\n* Claustrophobia\n* Based on the use of MRI, additional exclusion\u002Finclusion criteria are considered. Note that many contraindications for stimulation are common with MRI and thus are not repeated. Participants must not have metal in the body that is ferrous, will be required to remove all jewelry, must not have tattoos on the face or neck, must refrain from wearing metal in clothing (underwire) or active gear (possibility of metallic microparticle technology), must not be a metal worker or have an eye injury involving metal.\n* Anything that in the opinion of the investigator would place the participant at increased risk or preclude the participant's full compliance with or completion of the study\n* DSM-V diagnosis of present moderate or severe substance use disorder or alcohol use disorder, and past severe substance use disorder or alcohol use disorder, or psychotic disorder within the last 12 months",{"count":476,"type":21},72,[24],"Anhedonia, the inability to seek-out and experience pleasure, is a common symptom in depression that predicts treatment-resistance and is sometimes exacerbated by first-line antidepressants. In our previous research, we found that anhedonia decreases goal-directed behavior and its related neural activity. In this study, we will investigate target engagement from five-consecutive days of stimulation for participants that are within a unipolar major depressive episode and also have high symptoms of anhedonia.",[33,27],[481,482,483],"Transcranial alternating current stimulation","Goal-directed behavior","Cross-frequency coupling","2026-03-09",{"date":486,"type":43},"2026-03-11",{"date":488,"type":43},"2024-01-24",{"date":490,"type":21},"2026-07-31",{"name":492,"class":90},"Florida State University",{"id":494,"slug":495,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":128,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":91},"100509962","a-digitally-assisted-risk-reduction-platform-for-youth-at-high-risk-for-suicide-100509962","NCT05920252","A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide","Development and Testing of a Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide","Inclusion Criteria:\n\n* Written informed assent from adolescents ages 13-17 years old and permission from legal guardians, or consent from adolescents age 18 years old.\n* Receiving treatment at the Intensive Adolescent and Family DBT Pgogram\n* 13-18 years old\n* Owns a personal smartphone (Android or iPhone 7+)\n* Fluent in English\n\nExclusion Criteria:\n\n* Adolescents who require a higher level of care (i.e., are not admitted to the Intensive Outpatient DBT program)\n* Adolescents who are receiving treatment at the Intensive Adolescent and Family DBT program and have already been assigned a clinician",{"count":501,"type":21},78,[24],"Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to provide a unique understanding of risk factors, including psychological distress, anhedonia and behavioral withdrawal, and sleep disturbance among high-risk individuals. This project aims to enhance the effectiveness of the delivery of preventative health care to youth at risk for suicide by developing a comprehensive digital platform that allows practitioners to integrate mobile sensing data and HIPAA-compliant client communication tools into their management of these young people.",[76,505,27],"Mental Health Disorder",[164,507,302,508,509,68,66],"Depressive Disorder","Mental Disorders","Suicidal Behaviors","2026-03-02",{"date":512,"type":43},"2026-03-04",{"date":514,"type":43},"2024-08-14",{"date":145,"type":21},{"name":517,"class":50},"Ksana Health",{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":235,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":529,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":91},"100457726","developing-brain-imaging-analysis-expertise-for-personalizing-transcranial-electric-stimulation-in-anhedonia-treatment-of-patients-with-bipolar-depression-100457726","NCT05240352","Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression","Inclusion Criteria:\n\n* diagnosis of Bipolar Disorder and clinically significant anhedonia\n* mild symptoms of depression\n\nExclusion Criteria:\n\n* substance abuse\u002Fdependence and any use of drugs (except alcohol or nicotine) in the previous month of the baseline assessment\n* participants with personality disorder that would interfere with study participation according to clinical judgment\n* previous neurological conditions (epilepsy, traumatic brain injury, stroke, etc)\n* any severe, life-threatening non-psychiatric medical condition\n* specific contraindications for tDCS (metallic plates in the head)\n* Participants identified as acutely suicidal or severely agitated",{"count":525,"type":21},45,[24],"The purpose of this study is to investigate whether transcranial direct-current stimulation (tDCS) will engage reward-related brain circuitry, more specifically the uncinate fasciculus (UF) tract, which connects the orbitofrontal cortex (OFC) and nucleus accumbens (NAcc) regions. Also to evaluate whether the changes in the fractional anisotropy (FA) of the UF tract are associated with changes of clinical symptoms of anhedonia and finally to investigate the moderation role of simulated electric fields (EFs) in an association between FA of the UF and symptoms of anhedonia.",[27],[530],"bipolar depression","2026-02-13",{"date":533,"type":43},"2026-02-18",{"date":535,"type":43},"2022-10-06",{"date":537,"type":21},"2026-12-01",{"name":539,"class":90},"The University of Texas Health Science Center, Houston",{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":548,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":567,"locationsCount":568},"100619749","a-just-in-time-adaptive-intervention-for-suicide-safety-planning-in-adolescents-100619749","NCT07348666","A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents","BRITE 2.0: A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents (ViraSafe RCT (SBIR Phase 2))","ViraSafeRCT","Inclusion Criteria:\n\nYouth (minors):\n\n* 13-17 years old\n* Suicide attempt in the last year and ideation in the past month\n* English fluency and literacy\n* Parent or legal guardian willing and able to legally provide informed consent\n* Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan\n\nYouth (adults)\n\n* 18-24 years old\n* Recent suicide attempt or ideation with a plan\n* English fluency and literacy\n* Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan.\n\nExclusion Criteria:\n\nYouth (minors):\n\n* Unable to read\u002Funderstand English\n* Current manic or psychotic episode\n* Development disability precluding comprehension of study procedures\n* No routine access to a mobile phone, assessed by EHR review and during phone screen\n* No eligible parent or legal guardian to provide informed consent\n\nYouth (adults):\n\n* Unable to read\u002Funderstand English\n* Current manic or psychotic episode\n* Development disability precluding comprehension of study procedures\n* No routine access to a mobile phone, assessed by EHR review and during phone screen","24 Years",{"count":237,"type":21},[24],"Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to increase engagement with effective interventions such as suicide safety planning. The BRITE suicide safety planning app was developed on evidence-based principles and has undergone rigorous formative development and effectiveness evaluations. However, to optimize its functionality, commercial viability, and scale its implementation, issues related to user engagement needed to be addressed. This 3 month Pragmatic Randomized Trial will evaluate the impact of the ViraSafe app-an enhanced version of the BRITE suicide safety planning app-on improving engagement with coping skills and safety planning among suicidal adolescents by comparing its intervention components to those of the original BRITE app.",[76,505,27],[554,555,556,557,558,559,560],"depression","depressive disorder","mood disorder","mental disorders","suicidal behavior","suicidal thoughts","suicidal ideation","2026-01-29",{"date":563,"type":43},"2026-02-02",{"date":565,"type":21},"2026-02-16",{"date":116,"type":21},{"name":517,"class":50},3,{"id":570,"slug":571,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":11,"sex":16,"minAge":577,"maxAge":289,"enrollmentInfo":578,"targetDuration":4,"studyType":22,"phases":580,"briefSummary":581,"conditions":582,"keywords":583,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":91},"100521913","phase-4-dopaminergic-therapy-for-anhedonia---2-100521913","NCT06075771","Dopaminergic Therapy for Anhedonia - 2","Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression - 2","DTA-2","Inclusion Criteria:\n\n* a. willing and able to give written informed consent\n* b. men or women, 25-55 years of age\n* c. a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), current, as diagnosed by the Structured Clinical Interview for DSM-5\n* d. score of \\>10 on the Patient Health Questionnaire-9 (PHQ-9) or HAM-D score ≥18\n* e. off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, anxiolytics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine)\n* f. c-reactive protein (CRP) ≥2 mg\u002FL\n* g. PHQ-9 anhedonia score ≥2\n\nExclusion Criteria:\n\n* a. history or evidence (clinical or laboratory) of an autoimmune disorder\n* b. history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection\n* c. history of any type of cancer requiring treatment with more than minor surgery\n* d. unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing)\n* e. history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; history or current bipolar disorder; history or current gambling disorder; substance abuse\u002Fdependence within 6 months of study entry (as determined by standardized clinician interview)\n* f. active suicidal plan as determined by a score \\>3 on item #3 on the HAM-D\n* g. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms)\n* h. a history of a cognitive disorder or traumatic head injury involving loss of consciousness\n* i. pregnancy or lactation\n* j. use of gender affirming hormone therapy\n* k. chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), glucocorticoid containing medications or statins\n* l. use of NSAIDS, glucocorticoids, or statins at any time during the study\n* m. urine toxicology screen is positive for drugs of abuse, n. any contraindication for MRI scanning\n* o. intolerance, sensitivity or contraindication to carbidopa-levodopa (including history of narrow-angle glaucoma, melanoma, gastric and\u002For duodenal ulcers, bleeding disorders, or frequent migraines)","25 Years",{"count":579,"type":21},70,[293],"The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.",[27,164],[27,164],"2026-01-26",{"date":586,"type":43},"2026-01-28",{"date":588,"type":43},"2023-11-21",{"date":590,"type":21},"2027-01",{"name":202,"class":90},{"id":593,"slug":594,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":11,"sex":16,"minAge":128,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":22,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":91},"100604932","ecological-momentary-intervention-for-reward-in-anhedonia-100604932","NCT07155941","Ecological Momentary Intervention for Reward in Anhedonia","EMIRA","Inclusion Criteria:\n\n* German speaking\n* Smartphone available and willingness to participate in repeated training units and questions delivered via app\n* Clinically elevated anhedonia (SHAPS \\>= 25) and elevated depression (DASS-21-Depression \\>= 10), elevated anxiey (DASS-21-Anxiety \\>= 6) or elevated stress (DASS-21-Stress \\>= 10)\n\nExclusion Criteria:\n\n* Psychotropic medication\n* Psychotherapy currently ongoing or planned during participation\n* Suicidality, lifetime diagnosis of bipolar disorders or psychotic episodes",{"count":185,"type":21},[24],"The present study evaluates a two week ecological momentary intervention (EMI) in reducing anhedonia and psychological distress (i.e. elevated depression, stress and anxiety). Participants in the experimental group complete three daily exercises targeting reward-related processes, including positive mental imagery, savoring, gratitude, taking ownership for positive experience, and silver lining. These components were selected to improve reward anticipation as well as reward consumption and reward learning as the underlying mechanisms of anhedonia. An active control group receives progressive muscle relaxation training, matched in format and frequency. Exercise units are presented using audio recordings via smartphone app.",[27,393,603,164],"Stress","2026-01-07",{"date":606,"type":43},"2026-01-09",{"date":608,"type":43},"2025-06-18",{"date":610,"type":21},"2026-01",{"name":612,"class":90},"Philipps University Marburg",{"id":614,"slug":615,"hasResults":11,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":621,"enrollmentInfo":622,"targetDuration":4,"studyType":22,"phases":624,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":639,"locationsCount":4},"100615125","promoting-positive-emotions-in-adolescents-using-positive-events-training-an-indicated-approach-100615125","NCT07288541","Promoting Positive Emotions in Adolescents Using Positive Events Training: An Indicated Approach","Promoting Positive Emotions in Adolescents Using Positive Event Training: An Indicated Approach (iPET)","iPET","Inclusion Criteria:\n\n* 12-16 years (age)\n* moderate level of baseline depressive symptoms Exclusion Criteria: \u002F","16 Years",{"count":623,"type":21},36,[24],"Research shows that high positive emotionality is an essential ingredient in building resilience in youngsters, especially those with a vulnerability to develop depressive symptomatology. It may empower them against actual depression and its various long-term adverse outcomes. One way to achieve positive emotions is via the recollection and anticipation of specific positive events. Therefore, to cultivate positive emotions in young people, a user-friendly group training program was developed, translated from basic research findings: Positive Event Training (PET). Through PET, adolescents learn to solidify positive memories and positive plans for the future. In this project, a comprehensive evaluation of PET's efficacy is conducted using a robust methodology with vulnerable youth.",[627,27],"Emotional Distress",[629,32,630,631,632],"positive emotions","positive affect regulation","emotional distress","autobiographical thinking","2025-12-03",{"date":635,"type":43},"2025-12-17",{"date":637,"type":21},"2025-12",{"date":590,"type":21},{"name":640,"class":90},"KU Leuven",{"id":642,"slug":643,"hasResults":11,"nctId":644,"briefTitle":645,"officialTitle":645,"acronym":4,"eligibilityCriteria":646,"healthyVolunteers":157,"sex":287,"minAge":128,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":22,"phases":649,"briefSummary":650,"conditions":651,"keywords":655,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":148},"100544100","trueblue-clinical-study---investigating-the-use-of-a-mobile-phone-app-trueblue-for-monitoring-depression-and-anxiety-100544100","NCT06364488","TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety","Inclusion Criteria:\n\n\\- 18 years or older\n\n* Fluent in spoken and written English\n* Has capacity to provide consent\n* At least 12 weeks pregnant or less than 12 weeks postpartum\n* Access to internet connectivity\n* Access to a compatible smart phone device (for up to 10 participants, where needed through not having a personal device, this access may be provided through the study team).\n* Has a current GP within Nottinghamshire\n\nExclusion Criteria:\n\n* ● Current clinically diagnosed psychiatric disorder other than depression\n\n  * Previous history of a clinically diagnosed psychiatric disorder, other than depression and generalised anxiety disorder (including previous Psychosis, Bipolar Disorder, Personality Disorder, Substance Abuse Disorders, Eating Disorders)\n  * Clinical diagnosis of an Autistic Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Parkinson's Disease or other current Neurological Disorder.",{"count":648,"type":21},125,[24],"This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of pregnancy and 12 weeks post-partum), recruited across multiple sites in Nottinghamshire, United Kingdom (UK). An initial within-study pilot phase will assess key aspects of the study including recruitment rate, usability issues and a detailed understanding of any device related adverse events; prior to full recruitment of a total 125 participants over a total 14-month period.",[164,652,653,393,27,654],"Depression, Postpartum","Anxiety in Pregnancy","Perinatal Depression",[164,393,656],"Perinatal","2025-09-16",{"date":659,"type":43},"2025-09-19",{"date":661,"type":43},"2024-10-01",{"date":663,"type":21},"2026-12-30",{"name":665,"class":50},"BlueSkeye AI",{"id":667,"slug":668,"hasResults":11,"nctId":669,"briefTitle":670,"officialTitle":670,"acronym":671,"eligibilityCriteria":672,"healthyVolunteers":157,"sex":16,"minAge":59,"maxAge":673,"enrollmentInfo":674,"targetDuration":4,"studyType":22,"phases":676,"briefSummary":677,"conditions":678,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":91},"100596053","stress-trajectories-and-anhedonia-in-adolescence-research-study-100596053","NCT07040449","Stress Trajectories and Anhedonia in Adolescence Research Study","STAARS","Inclusion Criteria:\n\n* Age 13-15 years old at study entry\n* Ability to understand and sign an assent form\n* Meets study hearing and vision requirements\n\nExclusion Criteria:\n\n* Current use of antipsychotic medication\n* Current use of medications that would interfere with cardiovascular or endocrine assessments\n* Metal in the body or other MRI exclusion\n* Central nervous system disorder or brain injury that could confound brain imaging evaluations\n* Presence of a medical condition that would interfere with cardiovascular or endocrine assessments\n* Impaired intellectual functioning\n* Diagnosed with a neurodevelopmental disability","15 Years",{"count":675,"type":21},192,[24],"This project will examine how multiple biological measures from the brain and the body's stress response system contribute to anhedonia (the loss of pleasure) in adolescence. The goal of this project is to see if it is possible to combine these biological measures to describe different patterns of activity in the brain and body that adolescents may have in response to stress.\n\nThe main question this study aims to answer is whether different patterns of activity in the brain and body are related to whether adolescents develop anhedonia and how high or low levels of anhedonia are over time.\n\nThis study will enroll 192 adolescents who are between 13 and 15 years. Adolescents will complete tasks three times: at the beginning of the study, 10 months after that, and then 10 months after that. In total, they will be part of the study for 20 months. At each time, adolescents will complete surveys, provide samples of spit to measure hormones and provide pictures of their brain to measure brain activity, participate in mildly stressful tasks, and complete different activities that measure how they think. The investigators will also ask each adolescent's parent or legal guardian to answer some surveys about themselves and their child.",[27,679,680],"Stress Response","Adolescent Development",{"date":682,"type":43},"2025-06-27",{"date":684,"type":43},"2025-03-12",{"date":686,"type":21},"2030-02",{"name":316,"class":90},{"id":689,"slug":690,"hasResults":11,"nctId":691,"briefTitle":692,"officialTitle":693,"acronym":4,"eligibilityCriteria":694,"healthyVolunteers":157,"sex":16,"minAge":128,"maxAge":695,"enrollmentInfo":696,"targetDuration":4,"studyType":359,"phases":4,"briefSummary":698,"conditions":699,"keywords":702,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":710,"lastUpdatePostDateStruct":711,"startDateStruct":713,"completionDateStruct":715,"leadSponsor":717,"locationsCount":91},"100522286","reward-processing-and-depressive-subtypes-identifying-neural-biotypes-100522286","NCT06080646","Reward Processing and Depressive Subtypes: Identifying Neural Biotypes","Reward Processing and Depressive Subtypes: Identifying Neural Biotypes Related to Suicide Risk, Resilience, and Treatment Response","* Our studies require some in-person visits to our research lab, located at 42nd Ave and Clement St in San Francisco.\n* Because this study includes an MRI, part of the screening process will be to ensure you don't have any metal in your body, you do not have head or neck tattoos, and you are comfortable inside the MRI scanner.\n\nInclusion Criteria:\n\n* 18-70 years with a diagnosis of major depressive disorder (MDD) for MDD group, or without for unaffected comparison (UC) group\n* Negative metal screen for MRI safety\n* Normal (or corrected to normal) vision\n\nExclusion Criteria:\n\n* Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms)\n* Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms\n* Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology)\n* Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions\n* Known claustrophobia\n* Current Pregnancy\n* IQ estimate \\\u003C 70","70 Years",{"count":697,"type":21},150,"Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.",[164,507,33,700,701,27],"Major Depressive Episode","Depressive Symptoms",[703,704,705,453,452,454,706,707,708,709],"reward","motivation","EEG","amotivation","avolition","suicidality","suicide","2024-07-31",{"date":712,"type":43},"2024-08-02",{"date":714,"type":43},"2021-06-01",{"date":716,"type":21},"2025-09-01",{"name":718,"class":719},"San Francisco Veterans Affairs Medical Center","FED"]